Mutations associated with long QT syndrome
View Patent ↗The invention is based, at least in part, on the observation that the presence of particular biomarkers, e.g., particular mutations in any of the KCNQ1, KCNH2, SCN5A, KCNE1 and KCNE2 genes as identified in Tables 1-5 (and, in particular, those identified with an asterisk), is associated with Long QT Syndrome (LQTS).
1. A method for determining whether a subject suffers from or is predisposed to suffer from congenital long QT syndrome (LQTS) comprising
analyzing a biological sample from a subject for the allele present at KCNQ1 mutations 1075 C>T, 190 — 210del (in which nucleotides 80718 to 80738 of SEQ ID NO: 1 are deleted), 862 — 880del (in which nucleotides 208341 to 208359 of SEQ ID NO: 1 are deleted), 1265delA, and 1338 C>G,
detecting in the biological sample any one or more of the KCNQ1 mutations 1075 C>T, 190 — 210del, 862 — 880del, 1265delA, and 1338 C>G, and
determining that the subject suffers from or is predisposed to suffer from LQTS when any one or more of the KCNQ1 mutations 1075 C>T, 190 — 210del, 862 — 880del, 1265delA, and 1338 C>G is present in the biological sample.
2. A method for detecting a KCNQ1 variant, comprising
analyzing a biological sample from a subject for the allele present at KCNQ1 mutations 1075 C>T, 190 — 210del (in which nucleotides 80718 to 80738 of SEQ ID NO: 1 are deleted), 862 — 880del (in which nucleotides 208341 to 208359 of SEQ ID NO: 1 are deleted), 1265delA, and 1338 C>G, and
detecting in the biological sample any one or more of the KCNQ1 mutations 1075 C>T, 190 — 210del, 862 — 880del, 1265delA, and 1338 C>G.
3. The method of claim 1 or 2 , wherein the analyzing comprises using a technique selected from the group consisting of polymerase chain reaction (PCR) amplification reaction, reverse-transcriptase PCR analysis, single-strand conformation polymorphism analysis (SSCP), mismatch cleavage detection, heteroduplex analysis, Southern blot analysis, Western blot analysis, deoxyribonucleic acid sequencing, restriction fragment length polymorphism analysis, haplotype analysis, serotyping, and combinations or sub-combinations thereof.
4. The method of claim 1 or 2 , wherein the biological sample from the subject is selected from the group consisting of a fluid, blood fluids, vomit, intra-articular fluid, saliva, lymph, cystic fluid, urine, fluids collected by bronchial lavage, fluids collected by peritoneal rinsing, gynecological fluids, a blood sample or a component thereof, a tissue or component thereof, bone, connective tissue, cartilage, lung, liver, kidney, muscle tissue, heart, pancreas, and skin.